EuroBiotech Report—Novartis’ CAR-T data; Bioblast seeks help; Merck KGaA, F-Star partner; Novo and Innate in I-O pact

Welcome to the latest edition of our weekly EuroBiotech Report. We started the week with two big deals for European biopharmas as German Merck and the U.K.’s F-Star penned a new bispecific R&D deal, while Innate gained exclusive rights to Novo’s first-in-class clinical-stage anti-C5aR antibody, as Novo boosted its stake in the French biotech. And then, after ASCO, we saw Novartis reveal its long-awaited Juliet CAR-T data while Israel’s Bioblast has sought out life sciences advisory firm JSB-Partners to help it find either a partner or merger deal. Ben Adams. 

  1. As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed

It’s been a big week for CAR-T: Novartis, Juno, Kite, Bluebird Bio and Nanjing Legend Biotech all posted positive data for the cutting-edge experimental cancer class at ASCO, and now Novartis has revealed the long-awaited interim Juliet data for its CAR-T candidate at a Swiss conference. As it goes head-to-head with rival Kite Pharma.

  1. Israel's troubled Bioblast seeks partners, merger

Several months after abandoning plans for a securities offering, Israel’s Bioblast Pharma has asked JSB-Partners to help it seek out a partner or a merger to help lift it out of its troubles.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.
  1. Merck KGaA, F-Star in bispecific biobucks bonanza deal

The two countries’ governments may not be getting along right now as a long divorce plays out, but it’s a marriage of science for Germany’s Merck and Cambridge, U.K.-based F-Star as the two pair up for a new bispecific research deal.

  1. Innate Pharma and Novo Nordisk pen early I-O cancer drug deal

French biotech Innate Pharma has inked a new deal with Danish diabetes specialist Novo Nordisk that sees the latter boost its stake in the firm while Innate get its hands on a new I-O candidate.

And more articles of note >>

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.